Clinical outcomes, demographics and associative analysis of lung cancer patients with Lambert-Eaton myasthenic syndrome: Insights from the National Inpatient Sample (NIS) database.

e20134 Background: Lambert-Eaton myasthenic syndrome (LEMS) is a rare neuromuscular junction disorder that may present as a paraneoplastic syndrome or a primary autoimmune disorder. Approximately 60% of LEMS patients have an underlying tumor, with the paraneoplastic form predominantly associated with small cell lung cancer (SCLC). Understanding the clinical outcomes and risks associated in lung cancer patients with LEMS is crucial in effective management of such patients. Methods: This retrospective study utilized inpatient hospitalization data from the National Inpatient Sample (NIS) between January 1, 2016, and December 31, 2019. Data of patients with a primary or secondary discharge diagnosis of lung cancer (ICD10-CM codes C34, C78. 0, C46. 5, D02. 2) were obtained. Then, out of this population, we identified Lambert-Eaton myasthenic syndrome with ICD-10 codes (G70. 80, G70. 81, G73. 1). The objective was to run a descriptive analysis of clinical outcomes, risks, demographics and associations of LEMS in patients with lung cancer. Results: A total of 204 cases of lung cancer hospitalizations with LEMS were analyzed. The mean age was 68. 23 years, with a slight female (51. 72%) preponderance as compared to male (48. 28%). Race distribution revealed increased prevalence in White Caucasians (83%), followed by Black (7%), Hispanic (4. 5%), Asian or Pacific Islander (3%), Native American (0. 5%), and Other (2%). The majority were covered by Medicare (66. 33%), followed by private insurance (26. 13%). The mortality rate was 8. 9%, with a mean length of stay of 10. 35 days and mean hospital charges of 118, 676. Clinical outcomes and risks were analyzed, with sepsis occurring in 17. 6% of cases, pneumonia in 22. 5%, and acute respiratory failure in 26. 9%. Intubation/mechanical ventilation was necessary in 18. 1% of cases. The incidence of urinary tract infection (UTI) was 16. 7%, acute kidney injury (AKI) was 17. 2%, and venous thromboembolism (VTE) was 6. 4%. Additionally, interventions such as intravenous immunoglobulin (IVIG) therapy and blood transfusions were also noted. Conclusions: This study provides insights into the demographic characteristics and clinical outcomes of lung cancer patients with Lambert-Eaton myasthenic syndrome (LEMS). The findings highlight the need for comprehensive management strategies targeting associated complications like acute respiratory failure, intubation and need for mechanical ventilation, pneumonia, UTI, AKI, and VTE to improve patient outcomes, quality of care and effective patient education with regards to their diagnosis of LEMS in lung cancer.